Sigilon Therapeutics's Return On Capital Employed Overview
Portfolio Pulse from Benzinga Insights
Sigilon Therapeutics (NASDAQ:SGTX) reported Q1 sales of $4.86 million and a loss of $7.38 million, with a Return On Capital Employed (ROCE) of -0.22%. The negative ROCE suggests that management may not be effectively allocating their capital.
May 24, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sigilon Therapeutics reported Q1 sales of $4.86 million and a loss of $7.38 million, with a negative ROCE of -0.22%, indicating potential inefficiency in capital allocation.
The negative ROCE of -0.22% suggests that Sigilon Therapeutics may not be effectively allocating their capital, which could lead to poor performance and unfavorable long-term returns. This could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100